Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities

Dennis, M, Culligan, D, Karamitros, D et al. (8 more authors) (2013) Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities. Leukemia Research Reports, 2 (2). pp. 70-74. ISSN 2213-0489

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2013 The Authors. Published by Elsevier Ltd. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords: Myelodysplasia; Acute myeloid leukaemia; Chromosome 5; Lenalidomide; Chemotherapy
Dates:
  • Published: 25 November 2013
  • Published (online): 28 August 2013
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > Institute of Molecular Medicine (LIMM) (Leeds) > Section of Experimental Haematology (Leeds)
The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 10 Aug 2016 08:26
Last Modified: 10 Aug 2016 08:26
Published Version: https://dx.doi.org/10.1016/j.lrr.2013.07.003
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1016/j.lrr.2013.07.003
Related URLs:

Share / Export

Statistics